Burney Co/ 13F: New $3M Stake in Medpace (MEDP)

Burney Co. opened a new position in Medpace Holdings, Inc. (NasdaqGS: MEDP) by acquiring 4,764 shares valued at approximately $2.97 million in a filing on October 15, 2026.

What Changed in Burney Co.'s Medpace Position

This new stake reflects Burney Co.'s entry into Medpace Holdings, which is active in the healthcare sector, specializing in clinical research and medical development services. The fund's current holdings stand at 4,764 shares following this acquisition.

Other Institutional Activity in Medpace

Blackrock Inc. holds 2,498,248 shares of Medpace, valued at about $1.55 billion, having increased its stake by 27,915 shares recently. Price (T. Rowe) Associates Inc. has a significant position as well, with 2,069,677 shares worth approximately $1.28 billion after adding 1,780,171 shares. Vanguard Portfolio Management LLC owns 1,133,357 shares valued at about $700.9 million, having made a slight increase of 11,666 shares.

Medpace Holdings, Inc. Stock Down 0.5%

Medpace shares recently traded around $613.74 as of October 16, 2026. This price is above its 50-day moving average by 1.5% and its 200-day moving average by 16.8%. However, the stock is still about 9.5% below its 52-week high of $677.90.

Recent Earnings

In its latest earnings report, Medpace Holdings posted trailing twelve-month revenue of approximately $2.78 billion, reflecting a year-over-year revenue growth of 17.2%. The company has a net margin of 17.7% and a return on equity of 162.2%. The next earnings report is expected on October 21, 2026.

Insider Buying and Selling at Medpace Holdings, Inc.

Recently, August J. Troendle, the Chief Executive Officer, sold multiple blocks of shares: 10,880 shares on September 17 for around $6.75 million, 70,901 shares on September 22 valued at about $44.43 million, and 25,564 shares on September 28 worth approximately $1.59 million. These transactions were conducted before the filing date and were not executed under a Rule 10b5-1 plan.

Analysts Set New Price Targets

Analysts have maintained their ratings on Medpace, with Mizuho upgrading its target to $700 on October 7, 2026, from a previous target of $665. Barclays also adjusted its target to $625 from $600 on the same day. The consensus currently suggests a 'hold' rating with a mean price target of $595.92.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides services in clinical research and drug development across various regions, including North America and Europe. The firm supports the clinical development process from early stages to final phases, playing a crucial role in the healthcare sector.

Bottom Line

This filing reflects Burney Co.'s new stake in Medpace Holdings as of October 15, 2026. Investors should watch for the next earnings report on October 21, which could provide further insights into the company's performance. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.